Blueprint Medicines Corporation provided revenue guidance for the full year 2024. for the year, the company expects approximately $360 million to $390 million in global AYVAKIT net product revenues for all approved indications in 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
108.8 USD | +0.21% | +14.67% | +17.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.93% | 6.8B | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024